Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Microns strong fiscal Q4 results and upbeat Q1 outlook, alongside expectations of tighter AI-driven memory supply, dominate discussion. Despite bullish reactions to the fundamentals, traders are frustrated by the muted, choppy post-report move; many say expectations were already priced in and short-dated options were hit by volatility crush.

Alphabets AI news is driving discussion, particularly Gemini 4/Argon and reported benchmark strength, with Project Suncatchers planned test of AI chips in orbit adding to optimism about its AI ambitions. Traders are broadly bullish on the developments but also debate the significance of the claims and complain that sharp price swings have repeatedly erased gains.

AppLovins selloff is being tied to analyst concerns that e-commerce pixel adoption may not translate into meaningful growth, alongside questions about AXONs growth ceiling, Unity competition and litigation. Traders disagree over whether those risks signal a genuine slowdown or whether the companys growth and cash generation make the decline overdone; some also blame bearish research for intensifying the move.

Alphabet is drawing attention amid debate over its position in the AI race, especially whether Gemini 4 can compete with Metas Muse and other rival models. Traders are split between optimism about Googles AI efforts and concern that competition is weighing on the shares, with volatile price action fueling calls for a rebound and warnings of further declines.

A new change-of-control severance policy has fueled speculation about a possible buyout or strategic deal, though traders note there is no confirmed buyer or transaction. The conversation also focuses on the shipment of BlueBird 1416, with frustration that no firm launch date has been provided and the news has not produced sustained gains.

Microns earnings and guidance are the main read-through for SanDisk, with traders weighing whether strong AI-driven memory demand and tight NAND supply can lift the broader memory group. Optimists expect a sympathy move, while skeptics point to SNDKs weak, volatile price action and pressure from rising yields and oil prices.

Nu Holdings sharp move is drawing attention amid speculation about a potential Monzo acquisition; the company clarified that it is not pursuing a transaction with the UK digital bank. Traders are debating the deals possible strategic value and dilution risks, while some are unsure whether the Monzo news explains the price spike.

A Delaware judge ruled that Liquidias Yutrepia infringes two valid United Therapeutics patent claims covering treatment of PH-ILD, prompting a severe selloff as traders weigh possible restrictions on the drug against Liquidias plans to appeal and remove the indication from its label. The community is split between calling the decline an overreaction and viewing the unresolved remedies and legal risk as reason to avoid the stock or expect further losses.

SoFis prolonged share-price decline is driving the discussion, with many traders blaming prior share offerings and accusing CEO Anthony Noto of contradicting earlier comments about dilution. Others point to rising Treasury yields and rate-hike fears as pressure on rate-sensitive financial stocks, while some bulls argue the selloff is overdone and cite short interest as a potential source of support.

Capricors 24-month HOPE-3 extension data for deramiocel showed slower upper-limb decline in Duchenne muscular dystrophy patients, renewing attention ahead of the FDAs decision on the therapy. Many traders view the findings as supportive of approval and discuss a possible short squeeze, while skeptics argue the open-label results do not resolve prior FDA concerns about the trial data; approval remains uncertain.